Eli Lilly captures 60% of the $66 billion obesity drug market, driving its stock surge while Novo Nordisk lags.
Eli Lilly (LLY) has secured a dominant 60% share of the global obesity drug market, now valued at $66 billion and projected to reach $120 billion by 2030. The company’s Zepbound GLP-1 drug has fueled its leadership, contrasting with Novo Nordisk (NVO), which holds the remaining 27% of the market.
Lilly’s stock has risen 13.4% this year and 58% over the past 52 weeks, while Novo Nordisk’s shares are up just 0.4% this year and down 5% over the same period. Since July 2024, Novo Nordisk’s stock has dropped 62%, reflecting investor concerns over its market position.
Novo Nordisk recently launched Wegovy in pill form, prompting upward revisions to its sales and profit forecasts. However, Lilly’s current dominance in the obesity segment remains a key driver of its outperformance.